Author:
Britton Amadea,Embi Peter J.,Levy Matthew E.,Gaglani Manjusha,DeSilva Malini B.,Dixon Brian E.,Dascomb Kristin,Patel Palak,Schrader Kristin E.,Klein Nicola P.,Ong Toan C.,Natarajan Karthik,Hartmann Emily,Kharbanda Anupam B.,Irving Stephanie A.,Dickerson Monica,Dunne Margaret M.,Raiyani Chandni,Grannis Shaun J.,Stenehjem Edward,Zerbo Ousseny,Rao Suchitra,Han Jungmi,Sloan-Aagard Chantel,Griggs Eric P.,Weber Zachary A.,Murthy Kempapura,Fadel William F.,Grisel Nancy,McEvoy Charlene,Lewis Ned,Barron Michelle A.,Nanez Juan,Reese Sarah E.,Mamawala Mufaddal,Valvi Nimish R.,Arndorfer Julie,Goddard Kristin,Yang Duck-Hye,Fireman Bruce,Ball Sarah W.,Link-Gelles Ruth,Naleway Allison L.,Tenforde Mark W.
Publisher
Centers for Disease Control MMWR Office
Subject
Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology
Reference10 articles.
1. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19—COVID-NET, 10 states, March 2020–February 2022.;Singson;MMWR Morb Mortal Wkly Rep,2022
2. Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults—United States, August–December 2021.;Tenforde;MMWR Morb Mortal Wkly Rep,2022
3. Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—nine states, January–September 2021.;Embi;MMWR Morb Mortal Wkly Rep,2021
4. CDC. Use of COVID-19 vaccines in the United States. Interim clinical considerations for use of COVID-19 vaccines currently authorized or approved in the United States. Atlanta, GA: US Department of Health and Human Services; 2022.Accessed September 2, 2022. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html
5. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings.;Thompson;N Engl J Med,2021